Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Relief For Pradaxa: Praxbind Gets HTA Green Light

This article was originally published in Scrip

Executive Summary

Boehringer Ingelheim's Praxbind (idarucizumab), the antidote to the company's blood thinner Pradaxa (dabigatran), is now reimbursed in England, Wales and Ireland after national health technology appraisal bodies said there was no need to put the drug through a full assessment. The news gives Pradaxa a slight advantage over rival novel anticoagulants, which currently do not yet have antidotes, says Datamonitor Healthcare analyst Jack Allen.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register